Japan’s Ongoing Crisis on HPV Vaccination

Abstract

<jats:p>: The Japanese government suspended proactive recommendations for the HPV vaccine in June 2013. The suspension is now in its seventh year, despite all the data pointing to the safety of the HPV vaccine. We reported a high vaccine effectiveness in the group of women vaccinated before their first intercourse (93.9%). The prevalence of cross-protected types of HPV 31/45/52 was also lower in the vaccinated group, and the vaccine effectiveness was 67.7%. Furthermore, prevalence of HPV16, 31 and 52 infection rates in the vaccinated group were obviously lower than that in the unvaccinated group, and no one had HPV18 or 45 infection in the vaccinated group. The addition of a cross-protective effect toward HPV types 31/45/52 to HPV types 16/18, which is the direct target of the bivalent HPV vaccine, may possibly prevent around 82% of invasive cervical cancer cases in Japan. With regard to the preventive effect of histological abnormalities, we also reported significant reduction in incidence of cervical intraepithelial neoplasia (CIN)3 or worse. Thus, the efficacy of the vaccine has been demonstrated for precancerous disease, and the diverse symptoms after HPV vaccination are likely functional somatic. For the future of Japanese girls, there is a need to resume the proactive recommendation of HPV vaccination and for immediate action to be taken by the Japanese government.</jats:p>

Effect of a Brief Web-Based Educational Intervention on Willingness to Consider Human Papillomavirus Vaccination for Children in Japan: Randomized Controlled Trial

“…Nevertheless, the level of awareness regarding HPV, the resultant cancer (cervical cancer [CC]), and the vaccine needs to be higher in the Japanese population [ 2 , 3 ]. Although vaccination is the exclusive means of preventing HPV infection, the immunization rate has fallen below 1% owing to subsequent adverse events [ 4 ], which are regarded as functional disorders. These cases were reported repeatedly in Japanese media in sensational ways [ 2 , 4 ].…”

Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan

“…Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine (thereafter: Pfizer-BioNTech COVID-19 vaccine) was the first to be authorized for emergency use by the Ministry of Health, Labor and Welfare of Japan on February 14, 2021 [1]. However, due to the high awareness of reactogenicity following vaccines such as Human Papillomavirus (HPV) vaccines in the past, the Japanese people are cautious about COVID-19 vaccination [2]. Vaccine safety has been shown to be important to the Japanese public.…”

International comparison of trends in cancer mortality: Japan has fallen behind in screening-related cancers

“…Some local municipalities have started to send information or recommendation for the vaccination program to eligible women. Further actions are urgently needed at the national level ( 51 ).…”